Health Outcomes Liaisons (HOLs) play a critical role in conveying a therapy's safety and cost effectiveness to managed care groups. With billions in sales riding on effectively communicating with these organizations regarding products' cost effectiveness and safety, the biopharmaceutical industry has turned to HOLs to fill this critical communication role.
According to recent research from benchmarking firm, Best Practices, LLC, the majority of HOL programs are still in their early development, with only 25% of respondents indicating that their programs have been in place for seven years or longer. The HOL function is still in its infancy, and its ultimate value has yet to be fully realized. Despite this, HOLs deliver vital outcomes information that has the potential to guide all healthcare decision makers.
The report, "Health Outcomes Liaison Excellence: How the HOL Function Drives Value Across the Healthcare Industry," explores how leading companies deliver exceptional HOL services in an ever-changing business environment. The report also contains benchmarks and insights that will help pharmaceutical executives to better navigate and understand the activities of effective HOL programs at leading organizations.
Key issues addressed in the study include:
- Structure and resources of Health Outcome Liaisons (HOL) programs, including staffing, budget, geographic span, oversight responsibility, and services provided
- Scope, frequency, and timing of HOL services
- Methods HOLs use to engage internal and external customers and build lasting relationships
- Differences in roles of HOL, MSL, Key Account Manager and Sales staff
- Future trends expected to impact the HOL function
This benchmarking research drew participation from 23 HOL program leaders from 19 different pharmaceutical and medical device companies. In addition, deep-dive interviews were conducted with five participating companies to gather additional insights.
Aging populations are redefining the value of a healthy life year